JP2012518002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518002A5 JP2012518002A5 JP2011550246A JP2011550246A JP2012518002A5 JP 2012518002 A5 JP2012518002 A5 JP 2012518002A5 JP 2011550246 A JP2011550246 A JP 2011550246A JP 2011550246 A JP2011550246 A JP 2011550246A JP 2012518002 A5 JP2012518002 A5 JP 2012518002A5
- Authority
- JP
- Japan
- Prior art keywords
- layer
- nitazoxanide
- tizoxanide
- composition
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 80
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims description 47
- 229960002480 nitazoxanide Drugs 0.000 claims description 42
- 238000013270 controlled release Methods 0.000 claims description 14
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- 238000007906 compression Methods 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 208000005176 Hepatitis C Diseases 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000010410 layer Substances 0.000 claims 45
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Desacetyl-nitazoxanide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 claims 36
- 238000009472 formulation Methods 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 8
- 239000011230 binding agent Substances 0.000 claims 8
- 239000000314 lubricant Substances 0.000 claims 8
- 239000007909 solid dosage form Substances 0.000 claims 8
- 239000003085 diluting agent Substances 0.000 claims 6
- 239000007884 disintegrant Substances 0.000 claims 6
- 239000000945 filler Substances 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 5
- 239000011248 coating agent Substances 0.000 claims 5
- 238000000576 coating method Methods 0.000 claims 5
- -1 glidants Substances 0.000 claims 4
- 239000006186 oral dosage form Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000000377 silicon dioxide Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 239000000375 suspending agent Substances 0.000 claims 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims 2
- 229940038472 dicalcium phosphate Drugs 0.000 claims 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000011247 coating layer Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 3
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20228509P | 2009-02-13 | 2009-02-13 | |
| US61/202,285 | 2009-02-13 | ||
| PCT/US2010/024000 WO2010093854A1 (en) | 2009-02-13 | 2010-02-12 | Controlled release pharmaceutical formulations of nitazoxanide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075264A Division JP6117845B2 (ja) | 2009-02-13 | 2015-04-01 | ニタゾキサニドの制御放出医薬配合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518002A JP2012518002A (ja) | 2012-08-09 |
| JP2012518002A5 true JP2012518002A5 (https=) | 2014-12-04 |
| JP5726766B2 JP5726766B2 (ja) | 2015-06-03 |
Family
ID=42560126
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550246A Active JP5726766B2 (ja) | 2009-02-13 | 2010-02-12 | ニタゾキサニドの制御放出医薬配合物 |
| JP2015075264A Expired - Fee Related JP6117845B2 (ja) | 2009-02-13 | 2015-04-01 | ニタゾキサニドの制御放出医薬配合物 |
| JP2016239374A Expired - Fee Related JP6491174B2 (ja) | 2009-02-13 | 2016-12-09 | ニタゾキサニドの制御放出医薬配合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015075264A Expired - Fee Related JP6117845B2 (ja) | 2009-02-13 | 2015-04-01 | ニタゾキサニドの制御放出医薬配合物 |
| JP2016239374A Expired - Fee Related JP6491174B2 (ja) | 2009-02-13 | 2016-12-09 | ニタゾキサニドの制御放出医薬配合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US8524278B2 (https=) |
| EP (1) | EP2395840B1 (https=) |
| JP (3) | JP5726766B2 (https=) |
| KR (1) | KR101697800B1 (https=) |
| CN (2) | CN107260695A (https=) |
| AU (3) | AU2010213678B2 (https=) |
| BR (1) | BRPI1007945C8 (https=) |
| CA (1) | CA2752233C (https=) |
| CO (1) | CO6501159A2 (https=) |
| CY (1) | CY1123162T1 (https=) |
| DK (1) | DK2395840T3 (https=) |
| EA (1) | EA029018B1 (https=) |
| ES (1) | ES2797493T3 (https=) |
| HR (1) | HRP20201055T1 (https=) |
| HU (1) | HUE049501T2 (https=) |
| IL (1) | IL214624A0 (https=) |
| LT (1) | LT2395840T (https=) |
| MX (2) | MX381895B (https=) |
| PL (1) | PL2395840T3 (https=) |
| PT (1) | PT2395840T (https=) |
| SI (1) | SI2395840T1 (https=) |
| UA (1) | UA107564C2 (https=) |
| WO (1) | WO2010093854A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2636527C (en) * | 2006-01-09 | 2016-05-17 | Romark Laboratories, L.C. | Viral hepatitis treatment |
| SI2395840T1 (sl) | 2009-02-13 | 2020-08-31 | Romark Laboratories, L.C. | Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem |
| WO2013110975A1 (es) * | 2012-01-27 | 2013-08-01 | Siegfried Rhein S.A. De C.V. | Composición de nitazoxanida mejorada y proceso para prepararla |
| CA2864858A1 (en) * | 2012-02-20 | 2013-08-29 | Lupin Limited | Bilayer tablet of dronedarone |
| KR101639692B1 (ko) * | 2013-12-13 | 2016-07-14 | 제일약품주식회사 | 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물 |
| MX2017006083A (es) | 2014-11-11 | 2017-11-08 | Romark Laboratories Lc | Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma. |
| PT3436074T (pt) | 2016-03-31 | 2020-08-21 | Romark Laboratories Lc | Compostos tiazolida para tratamento de infeções virais |
| KR102410951B1 (ko) * | 2016-04-11 | 2022-06-20 | 장피트 | 담즙정체성 및 섬유증 질환의 치료 방법 |
| US10905680B2 (en) * | 2016-04-11 | 2021-02-02 | Genfit | Methods of treatment for cholestatic and fibrotic diseases |
| EA201992116A1 (ru) * | 2017-03-08 | 2020-01-29 | СИНРКС ФАРМА, ЭлЭлСи | Фармацевтические составы флороглюцинола и триметилфлороглюцинола |
| WO2018167103A1 (en) * | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2018195035A1 (en) | 2017-04-18 | 2018-10-25 | Romark Laboratories L.C. | Inhibition of protein disulfide-isomerase a3 |
| US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| WO2018230713A1 (ja) * | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| CN108524460B (zh) * | 2018-05-14 | 2021-01-01 | 佛山市南海东方澳龙制药有限公司 | 烯啶虫胺双层片 |
| WO2019241376A1 (en) | 2018-06-14 | 2019-12-19 | The Trustees Of Columbia University In The City Of New York | Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof |
| CN110025621A (zh) * | 2019-03-13 | 2019-07-19 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 替唑尼特和硝唑尼特在制备抗炎药物中的应用 |
| CN111012788B (zh) * | 2019-12-12 | 2021-01-15 | 武汉职业技术学院 | 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用 |
| WO2021125824A1 (ko) * | 2019-12-19 | 2021-06-24 | (주)셀트리온 | 시벤졸린 또는 이의 염을 포함하는 약학 제형 |
| US20230303504A1 (en) | 2020-07-20 | 2023-09-28 | Romark Laboratories, L.C. | Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine |
| MX2023002208A (es) | 2020-08-24 | 2023-05-17 | Romark Laboratories Lc | Uso de tiazolidas contra los coronavirus. |
| WO2022130406A1 (en) * | 2020-12-15 | 2022-06-23 | Cipla Limited | Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease |
| WO2023058046A1 (en) | 2021-10-05 | 2023-04-13 | Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) | An improved process for the preparation of nitazoxanide and intermediates thereof |
| CN114259492A (zh) * | 2021-12-21 | 2022-04-01 | 中以海德人工智能药物研发股份有限公司 | 硝唑尼特在治疗乙肝中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| JPH06316517A (ja) * | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| US5387598A (en) | 1994-04-13 | 1995-02-07 | Rossignol; Jean-Francois | Composition and galenic formulation suitable for combatting affections of the lower abdomen |
| US5578621A (en) | 1994-09-08 | 1996-11-26 | Romark Lab Lc | Benzamide derivatives |
| US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| MX9604483A (es) | 1994-09-08 | 1998-02-28 | Jean-Francois Rossignol | Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas. |
| CN100515420C (zh) * | 1997-05-07 | 2009-07-22 | 罗马克实验室有限公司 | 脱乙酰基硝噻醋柳胺和硝噻醋柳胺的药用组合物 |
| US5948440A (en) | 1997-12-17 | 1999-09-07 | Ranbaxy Laboratories Limited | Modified release matrix formulation of cefaclor and cephalexin |
| MXPA01004381A (es) | 1998-11-02 | 2005-09-08 | Elan Corp Plc | Composicion de multiparticulado de liberacion modificada. |
| GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
| DE10031043A1 (de) * | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
| JP4637338B2 (ja) * | 2000-09-22 | 2011-02-23 | 大塚製薬株式会社 | シロスタゾール有核錠 |
| ATE361060T1 (de) | 2000-09-29 | 2007-05-15 | Solvay Pharm Bv | Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung |
| US7074417B2 (en) | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
| NZ532096A (en) * | 2001-09-28 | 2006-10-27 | Mcneil Ppc Inc | Dosage forms having an inner core and outer shell with different shapes |
| BR0213079A (pt) | 2001-09-28 | 2004-11-09 | Sun Pharmaceutical Ind Ltd | Forma de dosagem para o tratamento da diabetes mellitus |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| PE20050335A1 (es) | 2003-08-07 | 2005-06-01 | Sb Pharmco Inc | Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion |
| GB0319874D0 (en) * | 2003-08-22 | 2003-09-24 | Glaxo Group Ltd | Novel formulation |
| UA90864C2 (en) | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
| WO2006070406A1 (en) * | 2004-12-29 | 2006-07-06 | J.B. Chemicals & Pharmaceuticals Ltd | Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof |
| AU2006235490A1 (en) | 2005-04-12 | 2006-10-19 | Romark Laboratories, L.C. | Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| CA2636527C (en) * | 2006-01-09 | 2016-05-17 | Romark Laboratories, L.C. | Viral hepatitis treatment |
| JP2006335771A (ja) * | 2006-09-22 | 2006-12-14 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
| US20080299188A1 (en) * | 2007-05-14 | 2008-12-04 | Pfizer Inc. | Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug |
| US20080286344A1 (en) * | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| ES2550755T3 (es) | 2007-08-03 | 2015-11-12 | Romark Laboratories, L.C. | Compuestos de tiazolida sustituidos con alquilsulfonilo |
| SI2395840T1 (sl) * | 2009-02-13 | 2020-08-31 | Romark Laboratories, L.C. | Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem |
-
2010
- 2010-02-12 SI SI201032014T patent/SI2395840T1/sl unknown
- 2010-02-12 ES ES10741758T patent/ES2797493T3/es active Active
- 2010-02-12 DK DK10741758.6T patent/DK2395840T3/da active
- 2010-02-12 US US12/656,704 patent/US8524278B2/en not_active Expired - Fee Related
- 2010-02-12 AU AU2010213678A patent/AU2010213678B2/en not_active Ceased
- 2010-02-12 CA CA2752233A patent/CA2752233C/en not_active Expired - Fee Related
- 2010-02-12 KR KR1020117020973A patent/KR101697800B1/ko not_active Expired - Fee Related
- 2010-02-12 PT PT107417586T patent/PT2395840T/pt unknown
- 2010-02-12 PL PL10741758T patent/PL2395840T3/pl unknown
- 2010-02-12 EA EA201190127A patent/EA029018B1/ru not_active IP Right Cessation
- 2010-02-12 MX MX2017006915A patent/MX381895B/es unknown
- 2010-02-12 HU HUE10741758A patent/HUE049501T2/hu unknown
- 2010-02-12 LT LTEP10741758.6T patent/LT2395840T/lt unknown
- 2010-02-12 JP JP2011550246A patent/JP5726766B2/ja active Active
- 2010-02-12 EP EP10741758.6A patent/EP2395840B1/en active Active
- 2010-02-12 WO PCT/US2010/024000 patent/WO2010093854A1/en not_active Ceased
- 2010-02-12 BR BRPI1007945A patent/BRPI1007945C8/pt not_active IP Right Cessation
- 2010-02-12 MX MX2011008530A patent/MX348282B/es active IP Right Grant
- 2010-02-12 HR HRP20201055TT patent/HRP20201055T1/hr unknown
- 2010-02-12 CN CN201710263825.6A patent/CN107260695A/zh active Pending
- 2010-02-12 CN CN2010800164251A patent/CN102395276A/zh active Pending
- 2010-12-02 UA UAA201110567A patent/UA107564C2/uk unknown
-
2011
- 2011-08-11 IL IL214624A patent/IL214624A0/en active IP Right Grant
- 2011-09-07 CO CO11115308A patent/CO6501159A2/es not_active Application Discontinuation
-
2013
- 2013-07-30 US US13/954,184 patent/US9351937B2/en not_active Expired - Fee Related
-
2015
- 2015-04-01 JP JP2015075264A patent/JP6117845B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-16 AU AU2016200971A patent/AU2016200971B2/en not_active Ceased
- 2016-04-29 US US15/141,921 patent/US9827227B2/en not_active Expired - Fee Related
- 2016-12-09 JP JP2016239374A patent/JP6491174B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-11 AU AU2017203148A patent/AU2017203148B2/en not_active Ceased
- 2017-11-16 US US15/814,850 patent/US10383855B2/en active Active
-
2019
- 2019-07-02 US US16/460,161 patent/US11426388B2/en active Active
-
2020
- 2020-07-07 CY CY20201100626T patent/CY1123162T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518002A5 (https=) | ||
| JP6491174B2 (ja) | ニタゾキサニドの制御放出医薬配合物 | |
| US9549941B2 (en) | Compositions and methods for treating hepatitis C virus | |
| RU2011123876A (ru) | Антисмысловые композиции и способы их получения и применения | |
| CN1440283A (zh) | 有机化合物的联合形式 | |
| PH12014501133B1 (en) | Compositions and methods for treating hepatitis c virus | |
| WO2014142607A1 (ko) | 약제학적 복합제제 | |
| CN1863512A (zh) | 控释药物组合物及其制备方法 | |
| WO2020089761A1 (en) | Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof | |
| CN112263581A (zh) | 一种治疗pe和ed的双层片复方制剂及其制备方法 | |
| US20050059697A1 (en) | Combination of organic compounds | |
| CN118236367A (zh) | 一种复方制剂及其制备方法 | |
| HK1165217B (en) | Controlled release pharmaceutical formulations of nitazoxanide | |
| HK1165217A (en) | Controlled release pharmaceutical formulations of nitazoxanide |